1. Home
  2. GALT vs REGCO Comparison

GALT vs REGCO Comparison

Compare GALT & REGCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

N/A

Current Price

$4.00

Market Cap

232.3M

Sector

Health Care

ML Signal

N/A

Logo Regency Centers Corporation 5.875% Series B Cumulative Redeemable Preferred Stock

REGCO

Regency Centers Corporation 5.875% Series B Cumulative Redeemable Preferred Stock

HOLD

Current Price

$22.41

Market Cap

0.0

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GALT
REGCO
Founded
2000
N/A
Country
United States
United States
Employees
N/A
500
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.3M
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GALT
REGCO
Price
$4.00
$22.41
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
783.5K
N/A
Earning Date
11-14-2025
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.76
N/A
52 Week High
$7.13
N/A

Technical Indicators

Market Signals
Indicator
GALT
REGCO
Relative Strength Index (RSI) 33.79 42.78
Support Level $3.53 $22.26
Resistance Level $7.13 $22.61
Average True Range (ATR) 0.68 0.18
MACD -0.27 0.01
Stochastic Oscillator 13.06 47.25

Price Performance

Historical Comparison
GALT
REGCO

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

About REGCO Regency Centers Corporation 5.875% Series B Cumulative Redeemable Preferred Stock

Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.

Share on Social Networks: